for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Laboratory Corp. of America Holdings

LH

Latest Trade

190.08USD

Change

1.81(+0.96%)

Volume

50,698

Today's Range

189.12

 - 

191.47

52 Week Range

98.02

 - 

206.74

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Labcorp, Infirmary Health Form Partnership To Provide Lab Services

Sept 29 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::LABCORP AND INFIRMARY HEALTH FORM STRATEGIC PARTNERSHIP TO PROVIDE LABORATORY SERVICES ACROSS HEALTHCARE SYSTEM.LABCORP - WILL HELP INFIRMARY HEALTH INCREASE CAPACITY FOR COVID-19 TESTING TO SUPPORT PATIENTS THROUGHOUT ALABAMA.LABCORP - CO & INFIRMARY HEALTH ENTERED MULTI-YEAR COLLABORATION TO PROVIDE LAB SERVICES TO PATIENTS & PROVIDERS THROUGHOUT EASTERN GULF COAST REGION.

Genfit And Labcorp Sign Exclusive Agreement To Commercialize A Novel Diagnostic Test For Liver Disease

Sept 28 (Reuters) - Genfit SA <GNFT.PA>::GENFIT AND LABCORP SIGN EXCLUSIVE AGREEMENT TO COMMERCIALIZE A NOVEL DIAGNOSTIC TEST FOR LIVER DISEASE.TEST IS EXPECTED TO BE AVAILABLE FROM LABCORP BY EARLY 2021.INNOVATIVE MULTI-BIOMARKER BLOOD TEST BASED ON GENFIT'S NIS4™ TECHNOLOGY IS SPECIFICALLY DESIGNED TO IDENTIFY PATIENTS WITH AT-RISK NON-ALCOHOLIC STEATOHEPATITIS (NASH).LABCORP TO COMMERCIALIZE TEST FOR CLINICAL CARE USE IN U.S. AND CANADA TO HELP IDENTIFY APPROXIMATELY 10 MILLION INDIVIDUALS AT RISK OF PROGRESSING TO LATE STAGE COMPLICATIONS DUE TO NASH AMONG TENS OF MILLIONS OF PEOPLE WITH METABOLIC RISK FACTORS AND SUSPECTED DISEASE.

Labcorp Announces Q2 Earnings Per Share $2.37

July 28 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::ANNOUNCES 2020 SECOND QUARTER RESULTS.Q2 EARNINGS PER SHARE $2.37.Q2 REVENUE $2.8 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.5 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.00 -- REFINITIV IBES DATA.Q2 ADJUSTED EARNINGS PER SHARE $2.57.Q2 FREE CASH FLOW OF $272 MILLION, UP FROM $168 MILLION LAST YEAR.PROCESSED MORE THAN 8.5 MILLION MOLECULAR COVID-19 TESTS TO DATE, INCREASED CAPACITY TO ABOUT 180 THOUSAND TESTS PER DAY.QTRLY LABCORP DIAGNOSTICS REVENUE WAS $1.69 BILLION, A DECREASE OF (3.9%) FROM $1.76 BILLION IN Q2 2019.QUARTER-END COVANCE DRUG DEVELOPMENT BACKLOG WAS $11.79 BILLION COMPARED TO $11.30 BILLION LAST QUARTER.CONTINUES TO NOT PROVIDE 2020 GUIDANCE.QTRLY COVANCE DRUG DEVELOPMENT REVENUE WAS $1.09 BILLION, A DECREASE OF (2.9%) FROM $1.13 BILLION IN Q2 2019.CONTINUES TO BE NEGATIVELY IMPACTED BY COVID-19 PANDEMIC, COMPANY'S OUTLOOK HAS IMPROVED ACROSS ENTERPRISE.IN LABCORP DIAGNOSTICS, DEMAND FOR ITS BASE BUSINESS CONTINUES TO BE BELOW THE COMPANY'S HISTORICAL LEVELS.CO HAS BEEN RESUMING REGULAR WORK SCHEDULES, IS PROCEEDING WITH MERIT ADJUSTMENTS AND WILL RETROACTIVELY REINSTATE 401(K) CONTRIBUTIONS.REMAINS ON TRACK TO DELIVER ABOUT $200 MILLION OF NET SAVINGS FROM ITS 3-YEAR DIAGNOSTICS LAUNCHPAD INITIATIVE BY END OF 2021.REMAINS ON TRACK TO DELIVER ABOUT $150 MILLION OF NET SAVINGS FROM ITS 3-YEAR DRUG DEVELOPMENT LAUNCHPAD INITIATIVE BY END OF 2020.

U.S. FDA Authorizes First Diagnostic Test For Screening Of People Without Known Or Suspected COVID-19 Infection

July 24 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::U.S.FDA - AUTHORIZES FIRST DIAGNOSTIC TEST FOR SCREENING OF PEOPLE WITHOUT KNOWN OR SUSPECTED COVID-19 INFECTION.U.S. FDA-REISSUANCE INCLUDES AUTHORIZATION FOR LABCORP TO TEST POOLED SAMPLES CONTAINING UPTO 5 INDIVIDUAL SWAB SPECIMENS COLLECTED UNDER OBSERVATION.U.S. FDA - REISSUED LABCORP COVID-19 RT-PCR TEST EMERGENCY USE AUTHORIZATION (EUA) TO INCLUDE TWO NEW INDICATIONS FOR USE.U.S. FDA- LABCORP TEST REMAINS PRESCRIPTION-ONLY.

Labcorp To Adopt Decentralized Clinical Trials, Expand Technology Ecosystem

May 28 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::LABCORP ACCELERATES ADOPTION OF DECENTRALIZED CLINICAL TRIALS, EXPANDS TECHNOLOGY ECOSYSTEM THROUGH ALLIANCE WITH MEDABLE.LABCORP - COVANCE IS EXPANDING DECENTRALIZED TRIALS TECHNOLOGY ECOSYSTEM THROUGH ALLIANCE WITH MEDABLE.LABCORP - COVANCE PATIENT & SITE INTERFACE WILL BE POWERED BY MEDABLE'S MODULAR SOFTWARE PLATFORM.

Labcorp Q1 Loss Per Share $3.27

April 29 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::ANNOUNCES 2020 FIRST QUARTER RESULTS.Q1 LOSS PER SHARE $3.27.Q1 REVENUE $2.82 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.74 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.95 -- REFINITIV IBES DATA.Q1 ADJUSTED EARNINGS PER SHARE $2.37.WITHDRAWS 2020 GUIDANCE AND TEMPORARILY SUSPENDS ITS SHARE REPURCHASE PROGRAM DUE TO UNPREDICTABILITY OF ONGOING COVID-19 PANDEMIC.IN LABCORP DIAGNOSTICS, DEMAND FOR TESTING DECLINED 50% TO 55% VERSUS COMPANY'S NORMAL DAILY LEVELS AT END OF Q1.RECORDED RESTRUCTURING CHARGES, SPECIAL ITEMS, IMPAIRMENTS, AND AMORTIZATION, WHICH TOGETHER TOTALED $558.5 MILLION IN QUARTER.QTRLY LABCORP DIAGNOSTICS REVENUE, ADJUSTING OUT INCREASE IN ACCOUNTS RECEIVABLE RESERVES WAS $1.70 BILLION, A DECREASE OF 1.2%.REDUCTION IN QTRLY DEMAND IN LABCORP DIAGNOSTICS IMPACTED TESTING VOLUMES BROADLY, BUT WAS HEAVILY WEIGHTED TOWARDS ROUTINE TESTS.QTRLY COVANCE DRUG DEVELOPMENT REVENUE, WAS $1.14 BILLION, AN INCREASE OF 6.4%.QTRLY LOWER ORGANIC REVENUE INCLUDES ESTIMATED NEGATIVE IMPACT FROM COVID-19 OF 4.9% & LOWER MEDICARE, MEDICAID PRICING AS A RESULT OF PAMA OF 0.7%.QTRLY VOLUME REDUCTION IN BASE BUSINESS OF LABCORP DIAGNOSTICS APPEARS TO HAVE STABILIZED.QUARTER-END COVANCE DRUG DEVELOPMENT BACKLOG WAS $11.30 BILLION.AT END OF QUARTER, COMPANY'S CASH BALANCE AND TOTAL DEBT WERE $323.6 MILLION AND $6.2 BILLION, RESPECTIVELY.

Labcorp Covid-19 Antibody Tests Available Nationwide With No Upfront Out-Of-Pocket Costs

April 27 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::LABCORP COVID-19 ANTIBODY TESTS AVAILABLE NATIONWIDE WITH NO UPFRONT OUT-OF-POCKET COSTS.LABCORP - LOCATIONS INCLUDE NEARLY 2,000 LABCORP PATIENT SERVICE CENTERS INCLUDING MORE THAN 100 LABCORP AT WALGREENS LOCATIONS.LABCORP - BY MID-MAY, LABCORP EXPECTS TO BE ABLE TO PERFORM 200,000 TESTS PER DAY.

Walgreens To Further Expand Covid-19 Testing With Plans To Open Drive-Thru Locations In 49 U.S. States And Puerto Rico

April 27 (Reuters) - Walgreens Boots Alliance Inc <WBA.O>::WALGREENS TO FURTHER EXPAND COVID-19 TESTING WITH PLANS TO OPEN DRIVE-THRU LOCATIONS IN 49 U.S. STATES AND PUERTO RICO.WALGREENS BOOTS ALLIANCE INC - CO & LABCORP EXPAND PARTNERSHIP TO HELP CO TRIPLE TESTING CAPACITY THROUGH USE OF LABCORP COVID-19 DIAGNOSTIC TEST.WALGREENS BOOTS ALLIANCE INC - ONCE ALL SITES ARE FULLY OPERATIONAL, WALGREENS EXPECTS TO TEST MORE THAN 50,000 PEOPLE EACH WEEK.

Labcorp Broadens Availability Of Covid-19 Serological Antibody Tests

April 22 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::LABCORP BROADENS AVAILABILITY OF COVID-19 SEROLOGICAL ANTIBODY TESTS TO HOSPITALS, HEALTHCARE ORGANIZATIONS AND THROUGH ITS PATIENT SERVICE CENTERS.LABCORP - BY MID-MAY, LABCORP EXPECTS TO BE ABLE TO PERFORM SEVERAL HUNDRED THOUSAND TESTS PER WEEK.LABCORP - HAS BUILT CAPACITY TO PERFORM OVER 50,000 SEROLOGICAL TESTS/DAY, COMPLETE THOSE TESTS WITHIN AVERAGE OF 1-3 DAYS FROM TIME SPECIMEN IS PICKED UP.

Labcorp Covid-19 At-Home Test Kit Receives FDA Emergency Use Authorization

April 21 (Reuters) - Laboratory Corporation of America Holdings <LH.N>::LABCORP COVID-19 AT-HOME TEST KIT RECEIVES FDA EMERGENCY USE AUTHORIZATION.LABCORP - INTENDS TO MAKE COVID-19 SELF-COLLECTION KITS AVAILABLE TO CONSUMERS IN COMING WEEKS.LABCORP - EUA PERMITS NASAL SWAB SPECIMENS TO BE COLLECTED AT HOME USING PIXEL BY LABCORP COVID-19 TEST HOME COLLECTION KIT.LABCORP - COVID-19 AT-HOME TEST KIT WILL BE OFFERED THROUGH COMPANY'S PIXEL BY LABCORP PLATFORM.LABCORP - CO'S COVID-19 TEST HOME COLLECTION KIT AUTHORIZED BY FDA UNDER EUA ONLY FOR DETECTION OF NUCLEIC ACID FROM SARS-COV-2, NOT OTHER VIRUSES,PATHOGENS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up